Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05529706 · ClinicalTrials.gov registry record · NA

Community-based Brain Health Program to Address Dementia Risk

A NA study of Alzheimer Disease and Dementia, sponsored by Posit Science Corporation.

Completed
Registry status
NA
Development phase
86
Enrollment target
1
Study location

NCT05529706 is a NA study of Alzheimer Disease and Dementia that has completed, run by Posit Science Corporation. The registered enrollment target is 86 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05529706, a NA study of Alzheimer Disease and Dementia, has completed, sponsored by Posit Science Corporation.

COMPLETED
Registry status
NA
Development phase
86 participants
Enrollment target
1
Study location

Study Summary

This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions. The goal of this study is to evaluate the Brain Health Program in individuals with identified risk factors for the onset of dementia and to prepare for a large-scale efficacy trial in this population.

Interventions

  • OTHER Brain Health Program

Study Locations (1)

California

  • YMCA of San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2023-04-24
Est. Completion 2024-10-18
Phase NA

Sponsor

Posit Science Corporation

30 total trials

What the Registry Record Tells You About NCT05529706

The ClinicalTrials.gov registry entry for NCT05529706 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Posit Science Corporation, which has 30 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Brain Health Program is the first listed.

NCT05529706 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05529706 about?

NCT05529706 is a clinical study titled "Community-based Brain Health Program to Address Dementia Risk". This is a validation study to evaluate the acceptability, feasibility and preliminary efficacy of the Brain Health Program, a multimodal curriculum covering dementia risk factors and evidence-based change interventions. The goal of this study is to evaluate the Brain Health Program in individuals wi...

What is the current status of trial NCT05529706?

This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2023-04-24. Estimated completion is 2024-10-18.

What conditions does trial NCT05529706 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia.

What interventions are being tested in trial NCT05529706?

The interventions under investigation include: Brain Health Program (OTHER).

Who is sponsoring clinical trial NCT05529706?

This trial is sponsored by Posit Science Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05529706 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.